I have seen plenty of companies with impressive technology struggle to gain traction - not because the product lacked value, but because the company had not figured out how to make that value matter to the people who could help bring it to market.

In clinical research, CROs can be among those people.

But simply selling technology to a CRO does not create a meaningful partnership. Neither does putting a rebate into an agreement and calling it a partner program.

A real CRO partnership begins with a much more important question:

How does this technology help the CRO compete, win business, and deliver better results for its customers?

If that question cannot be answered convincingly, there is no foundation for a productive CRO partnership.

The right technology solution can become part of a CRO’s operational infrastructure. It can help the CRO solve a recurring problem, differentiate its offering, and strengthen the case it makes to sponsors.

That is a far more powerful position than being another vendor on a preferred-provider list.

I look for technologies that can create that kind of advantage - solutions capable of becoming repeatable, scalable components of how a CRO operates and wins. Then I help the technology company position the solution properly, identify the right CROs and the right people within them, and build a commercial model that gives both sides a genuine reason to invest.

Sometimes that means architecting a formal CRO partner program. Sometimes it means developing the strategy, messaging, and relationships that must come first. The answer depends on the company, the technology, and its stage of readiness.

Much of my career has been spent with emerging solution providers, and I understand the particular challenges they face. In a startup, roles change quickly, institutional knowledge is thin, and every important hire or commercial decision carries disproportionate weight.

But I have also learned that the need for a thoughtful CRO strategy is not limited to early-stage companies.

Established clinical technology companies can have strong products, experienced teams, and substantial market presence - and still lack a deliberate, scalable approach to CRO partnering. In some cases, the opportunity is not to build the company. It is to unlock a growth channel that has never been fully developed.

The common denominator is not company size. It is the opportunity to help a clinical technology solution company turn CRO relationships into a competitive growth strategy.

At this point in my career, I have worked with and closely observed a great many clinical technology solution companies.

I have seen great products fail to gain traction. I have seen average products succeed because the company understood its market. I have seen talented people placed in the wrong roles, and less obvious candidates become indispensable when given the right opportunity. I have watched strategies that looked good in a presentation collapse when exposed to the realities of selling into clinical research.

That history gives me pattern recognition - but it has not made me formulaic.

Every company is different. Every technology has to earn its place. Every CRO relationship has its own politics, priorities, and timing. My role is to understand those realities, tell my clients what I genuinely think, and help them pursue the opportunities that make sense.

I am not interested in creating activity for activity’s sake. I want to help good clinical technology gain commercial traction by enabling CROs to use it to compete more effectively.

That is the work I know, the work I remain passionate about, and the value Arlen Consulting Group brings to clinical technology solution providers serious about building an impactful CRO channel.